Induction of TNF-?, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells
We have previously demonstrated doxorubicin-induced urokinase (uPA) and interleukin-8 (IL-8) expression in human H69 small-cell lung carcinoma (SCLC) cells by a microarray technique using Human Cancer Chip version 2, in which 425 human "cancer-related" genes are spotted on the plates. The...
Gespeichert in:
Veröffentlicht in: | Cancer chemotherapy and pharmacology 2003-11, Vol.52 (5), p.391-398 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 398 |
---|---|
container_issue | 5 |
container_start_page | 391 |
container_title | Cancer chemotherapy and pharmacology |
container_volume | 52 |
creator | Niiya, Masami Niiya, Kenji Kiguchi, Toru Shibakura, Misako Asaumi, Noboru Shinagawa, Katsuji Ishimaru, Fumihiko Kiura, Katsuyuki Ikeda, Kazuma Ueoka, Hiroshi Tanimoto, Mitsune |
description | We have previously demonstrated doxorubicin-induced urokinase (uPA) and interleukin-8 (IL-8) expression in human H69 small-cell lung carcinoma (SCLC) cells by a microarray technique using Human Cancer Chip version 2, in which 425 human "cancer-related" genes are spotted on the plates. The microarray analysis also revealed a significant induction of tumor necrosis factor-alpha (TNF-alpha), and doxorubicin-induced macrophage chemoattractant protein-1 (MCP-1) expression was demonstrated by an RNase protection assay. We extended the study by testing the effects of doxorubicin on the induction of TNF-alpha, uPA, IL-8 and MCP-1 in other types of lung carcinoma cells. We investigated the effects of doxorubicin on the expression of TNF-alpha, uPA, IL-8 and MCP-1 in 12 human lung carcinoma cell lines, including five SCLC, three adenocarcinoma and four squamous cell carcinoma cells. The surface expression of their receptors was also investigated. TNF-alpha was significantly induced in three cell lines, H69, SBC-7 (SCLC) and PC-9 (adenocarcinoma), uPA in five cell lines, H69, SBC-7, EBC-1 (squamous cell), EBC-2 (squamous cell), and Sq-1 (squamous cell), IL-8 in three cell lines, H69, PC-9 and EBC-1, and MCP-1 in five cell lines, H69, SBC-3 (SCLC), SBC-7, PC-9 and Sq-1. In H69 cells, TNF-alpha antigen levels were increased approximately fivefold in the conditioned medium of doxorubicin-treated cells, in parallel with an increase in mRNA levels. As with uPA and IL-8, the maximum induction was observed at the "sublethal" concentrations of 2 and 4 microM at which cell growth was slightly inhibited 24 h after treatment. Furthermore, the cells did not express receptors including types I and II TNF-alpha receptors, uPA receptor (uPAR), C-x-C-chemokine receptor-1 (CXCR-1), or C-C-chemokine receptor-2, corresponding to TNF-alpha, uPA, IL-8 and MCP-1, respectively, that were induced by doxorubicin in the cells, although SBC-7 cells expressed uPAR, and EBC-1 cells expressed CXCR-1. TNF-alpha, uPA, IL-8 and MCP-1 induced and secreted from tumor cells upon doxorubicin stimulation may activate surrounding cells expressing the receptors such as neutrophils and monocytes/macrophages in a paracrine fashion. TNF-alpha is a major proinflammatory cytokine, and IL-8 and MCP-1 are major chemoattractants for neutrophils and monocytes/macrophages, respectively. Furthermore, uPA activates matrix metalloproteinase 9 which can truncate and activate IL-8. Thus, the simultaneous induction of TNF |
doi_str_mv | 10.1007/s00280-003-0665-1 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_213496314</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>689862201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1834-fe88abd003b632e520f0f749c51a36b3fe1563a72d13312439ae54093cfa726e3</originalsourceid><addsrcrecordid>eNotkE1LAzEQhoMoWKs_wFvw3Ogkk_06SSlWC1V7qOeQzSa6ZbupSRfaf29KhYGBl5eZh4eQew6PHKB4igCiBAaADPI8Y_yCjLhEwaCUeElGgFKyrAB5TW5i3ACA5Igjsl70zWD2re-pd3T9MWfPEzqsphO6WLKS6r6h77MV47Q-0sYffBjq1rQ9TfMzbHVPu6H_pkaHFPqtpsZ2XbwlV0530d797zH5mr-sZ29s-fm6mE2XzPASJXO2LHXdJOY6R2EzAQ5cISuTcY15jc7yLEddiCahciGx0jaTUKFxKcwtjsnD-e4u-N_Bxr3a-CH06aUSHGWVY1IwJvxcMsHHGKxTu9BudTgqDurkTp3dqcShTu4Uxz_XAF23</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213496314</pqid></control><display><type>article</type><title>Induction of TNF-?, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells</title><source>SpringerLink Journals - AutoHoldings</source><creator>Niiya, Masami ; Niiya, Kenji ; Kiguchi, Toru ; Shibakura, Misako ; Asaumi, Noboru ; Shinagawa, Katsuji ; Ishimaru, Fumihiko ; Kiura, Katsuyuki ; Ikeda, Kazuma ; Ueoka, Hiroshi ; Tanimoto, Mitsune</creator><creatorcontrib>Niiya, Masami ; Niiya, Kenji ; Kiguchi, Toru ; Shibakura, Misako ; Asaumi, Noboru ; Shinagawa, Katsuji ; Ishimaru, Fumihiko ; Kiura, Katsuyuki ; Ikeda, Kazuma ; Ueoka, Hiroshi ; Tanimoto, Mitsune</creatorcontrib><description>We have previously demonstrated doxorubicin-induced urokinase (uPA) and interleukin-8 (IL-8) expression in human H69 small-cell lung carcinoma (SCLC) cells by a microarray technique using Human Cancer Chip version 2, in which 425 human "cancer-related" genes are spotted on the plates. The microarray analysis also revealed a significant induction of tumor necrosis factor-alpha (TNF-alpha), and doxorubicin-induced macrophage chemoattractant protein-1 (MCP-1) expression was demonstrated by an RNase protection assay. We extended the study by testing the effects of doxorubicin on the induction of TNF-alpha, uPA, IL-8 and MCP-1 in other types of lung carcinoma cells. We investigated the effects of doxorubicin on the expression of TNF-alpha, uPA, IL-8 and MCP-1 in 12 human lung carcinoma cell lines, including five SCLC, three adenocarcinoma and four squamous cell carcinoma cells. The surface expression of their receptors was also investigated. TNF-alpha was significantly induced in three cell lines, H69, SBC-7 (SCLC) and PC-9 (adenocarcinoma), uPA in five cell lines, H69, SBC-7, EBC-1 (squamous cell), EBC-2 (squamous cell), and Sq-1 (squamous cell), IL-8 in three cell lines, H69, PC-9 and EBC-1, and MCP-1 in five cell lines, H69, SBC-3 (SCLC), SBC-7, PC-9 and Sq-1. In H69 cells, TNF-alpha antigen levels were increased approximately fivefold in the conditioned medium of doxorubicin-treated cells, in parallel with an increase in mRNA levels. As with uPA and IL-8, the maximum induction was observed at the "sublethal" concentrations of 2 and 4 microM at which cell growth was slightly inhibited 24 h after treatment. Furthermore, the cells did not express receptors including types I and II TNF-alpha receptors, uPA receptor (uPAR), C-x-C-chemokine receptor-1 (CXCR-1), or C-C-chemokine receptor-2, corresponding to TNF-alpha, uPA, IL-8 and MCP-1, respectively, that were induced by doxorubicin in the cells, although SBC-7 cells expressed uPAR, and EBC-1 cells expressed CXCR-1. TNF-alpha, uPA, IL-8 and MCP-1 induced and secreted from tumor cells upon doxorubicin stimulation may activate surrounding cells expressing the receptors such as neutrophils and monocytes/macrophages in a paracrine fashion. TNF-alpha is a major proinflammatory cytokine, and IL-8 and MCP-1 are major chemoattractants for neutrophils and monocytes/macrophages, respectively. Furthermore, uPA activates matrix metalloproteinase 9 which can truncate and activate IL-8. Thus, the simultaneous induction of TNF-alpha, uPA, IL-8 and MCP-1 may enhance the interaction between tumor and inflammatory/immune cells, and augment cytotoxicity.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-003-0665-1</identifier><language>eng</language><publisher>Heidelberg: Springer Nature B.V</publisher><ispartof>Cancer chemotherapy and pharmacology, 2003-11, Vol.52 (5), p.391-398</ispartof><rights>Copyright Springer-Verlag 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1834-fe88abd003b632e520f0f749c51a36b3fe1563a72d13312439ae54093cfa726e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Niiya, Masami</creatorcontrib><creatorcontrib>Niiya, Kenji</creatorcontrib><creatorcontrib>Kiguchi, Toru</creatorcontrib><creatorcontrib>Shibakura, Misako</creatorcontrib><creatorcontrib>Asaumi, Noboru</creatorcontrib><creatorcontrib>Shinagawa, Katsuji</creatorcontrib><creatorcontrib>Ishimaru, Fumihiko</creatorcontrib><creatorcontrib>Kiura, Katsuyuki</creatorcontrib><creatorcontrib>Ikeda, Kazuma</creatorcontrib><creatorcontrib>Ueoka, Hiroshi</creatorcontrib><creatorcontrib>Tanimoto, Mitsune</creatorcontrib><title>Induction of TNF-?, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells</title><title>Cancer chemotherapy and pharmacology</title><description>We have previously demonstrated doxorubicin-induced urokinase (uPA) and interleukin-8 (IL-8) expression in human H69 small-cell lung carcinoma (SCLC) cells by a microarray technique using Human Cancer Chip version 2, in which 425 human "cancer-related" genes are spotted on the plates. The microarray analysis also revealed a significant induction of tumor necrosis factor-alpha (TNF-alpha), and doxorubicin-induced macrophage chemoattractant protein-1 (MCP-1) expression was demonstrated by an RNase protection assay. We extended the study by testing the effects of doxorubicin on the induction of TNF-alpha, uPA, IL-8 and MCP-1 in other types of lung carcinoma cells. We investigated the effects of doxorubicin on the expression of TNF-alpha, uPA, IL-8 and MCP-1 in 12 human lung carcinoma cell lines, including five SCLC, three adenocarcinoma and four squamous cell carcinoma cells. The surface expression of their receptors was also investigated. TNF-alpha was significantly induced in three cell lines, H69, SBC-7 (SCLC) and PC-9 (adenocarcinoma), uPA in five cell lines, H69, SBC-7, EBC-1 (squamous cell), EBC-2 (squamous cell), and Sq-1 (squamous cell), IL-8 in three cell lines, H69, PC-9 and EBC-1, and MCP-1 in five cell lines, H69, SBC-3 (SCLC), SBC-7, PC-9 and Sq-1. In H69 cells, TNF-alpha antigen levels were increased approximately fivefold in the conditioned medium of doxorubicin-treated cells, in parallel with an increase in mRNA levels. As with uPA and IL-8, the maximum induction was observed at the "sublethal" concentrations of 2 and 4 microM at which cell growth was slightly inhibited 24 h after treatment. Furthermore, the cells did not express receptors including types I and II TNF-alpha receptors, uPA receptor (uPAR), C-x-C-chemokine receptor-1 (CXCR-1), or C-C-chemokine receptor-2, corresponding to TNF-alpha, uPA, IL-8 and MCP-1, respectively, that were induced by doxorubicin in the cells, although SBC-7 cells expressed uPAR, and EBC-1 cells expressed CXCR-1. TNF-alpha, uPA, IL-8 and MCP-1 induced and secreted from tumor cells upon doxorubicin stimulation may activate surrounding cells expressing the receptors such as neutrophils and monocytes/macrophages in a paracrine fashion. TNF-alpha is a major proinflammatory cytokine, and IL-8 and MCP-1 are major chemoattractants for neutrophils and monocytes/macrophages, respectively. Furthermore, uPA activates matrix metalloproteinase 9 which can truncate and activate IL-8. Thus, the simultaneous induction of TNF-alpha, uPA, IL-8 and MCP-1 may enhance the interaction between tumor and inflammatory/immune cells, and augment cytotoxicity.</description><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNotkE1LAzEQhoMoWKs_wFvw3Ogkk_06SSlWC1V7qOeQzSa6ZbupSRfaf29KhYGBl5eZh4eQew6PHKB4igCiBAaADPI8Y_yCjLhEwaCUeElGgFKyrAB5TW5i3ACA5Igjsl70zWD2re-pd3T9MWfPEzqsphO6WLKS6r6h77MV47Q-0sYffBjq1rQ9TfMzbHVPu6H_pkaHFPqtpsZ2XbwlV0530d797zH5mr-sZ29s-fm6mE2XzPASJXO2LHXdJOY6R2EzAQ5cISuTcY15jc7yLEddiCahciGx0jaTUKFxKcwtjsnD-e4u-N_Bxr3a-CH06aUSHGWVY1IwJvxcMsHHGKxTu9BudTgqDurkTp3dqcShTu4Uxz_XAF23</recordid><startdate>20031101</startdate><enddate>20031101</enddate><creator>Niiya, Masami</creator><creator>Niiya, Kenji</creator><creator>Kiguchi, Toru</creator><creator>Shibakura, Misako</creator><creator>Asaumi, Noboru</creator><creator>Shinagawa, Katsuji</creator><creator>Ishimaru, Fumihiko</creator><creator>Kiura, Katsuyuki</creator><creator>Ikeda, Kazuma</creator><creator>Ueoka, Hiroshi</creator><creator>Tanimoto, Mitsune</creator><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20031101</creationdate><title>Induction of TNF-?, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells</title><author>Niiya, Masami ; Niiya, Kenji ; Kiguchi, Toru ; Shibakura, Misako ; Asaumi, Noboru ; Shinagawa, Katsuji ; Ishimaru, Fumihiko ; Kiura, Katsuyuki ; Ikeda, Kazuma ; Ueoka, Hiroshi ; Tanimoto, Mitsune</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1834-fe88abd003b632e520f0f749c51a36b3fe1563a72d13312439ae54093cfa726e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niiya, Masami</creatorcontrib><creatorcontrib>Niiya, Kenji</creatorcontrib><creatorcontrib>Kiguchi, Toru</creatorcontrib><creatorcontrib>Shibakura, Misako</creatorcontrib><creatorcontrib>Asaumi, Noboru</creatorcontrib><creatorcontrib>Shinagawa, Katsuji</creatorcontrib><creatorcontrib>Ishimaru, Fumihiko</creatorcontrib><creatorcontrib>Kiura, Katsuyuki</creatorcontrib><creatorcontrib>Ikeda, Kazuma</creatorcontrib><creatorcontrib>Ueoka, Hiroshi</creatorcontrib><creatorcontrib>Tanimoto, Mitsune</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niiya, Masami</au><au>Niiya, Kenji</au><au>Kiguchi, Toru</au><au>Shibakura, Misako</au><au>Asaumi, Noboru</au><au>Shinagawa, Katsuji</au><au>Ishimaru, Fumihiko</au><au>Kiura, Katsuyuki</au><au>Ikeda, Kazuma</au><au>Ueoka, Hiroshi</au><au>Tanimoto, Mitsune</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Induction of TNF-?, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><date>2003-11-01</date><risdate>2003</risdate><volume>52</volume><issue>5</issue><spage>391</spage><epage>398</epage><pages>391-398</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><abstract>We have previously demonstrated doxorubicin-induced urokinase (uPA) and interleukin-8 (IL-8) expression in human H69 small-cell lung carcinoma (SCLC) cells by a microarray technique using Human Cancer Chip version 2, in which 425 human "cancer-related" genes are spotted on the plates. The microarray analysis also revealed a significant induction of tumor necrosis factor-alpha (TNF-alpha), and doxorubicin-induced macrophage chemoattractant protein-1 (MCP-1) expression was demonstrated by an RNase protection assay. We extended the study by testing the effects of doxorubicin on the induction of TNF-alpha, uPA, IL-8 and MCP-1 in other types of lung carcinoma cells. We investigated the effects of doxorubicin on the expression of TNF-alpha, uPA, IL-8 and MCP-1 in 12 human lung carcinoma cell lines, including five SCLC, three adenocarcinoma and four squamous cell carcinoma cells. The surface expression of their receptors was also investigated. TNF-alpha was significantly induced in three cell lines, H69, SBC-7 (SCLC) and PC-9 (adenocarcinoma), uPA in five cell lines, H69, SBC-7, EBC-1 (squamous cell), EBC-2 (squamous cell), and Sq-1 (squamous cell), IL-8 in three cell lines, H69, PC-9 and EBC-1, and MCP-1 in five cell lines, H69, SBC-3 (SCLC), SBC-7, PC-9 and Sq-1. In H69 cells, TNF-alpha antigen levels were increased approximately fivefold in the conditioned medium of doxorubicin-treated cells, in parallel with an increase in mRNA levels. As with uPA and IL-8, the maximum induction was observed at the "sublethal" concentrations of 2 and 4 microM at which cell growth was slightly inhibited 24 h after treatment. Furthermore, the cells did not express receptors including types I and II TNF-alpha receptors, uPA receptor (uPAR), C-x-C-chemokine receptor-1 (CXCR-1), or C-C-chemokine receptor-2, corresponding to TNF-alpha, uPA, IL-8 and MCP-1, respectively, that were induced by doxorubicin in the cells, although SBC-7 cells expressed uPAR, and EBC-1 cells expressed CXCR-1. TNF-alpha, uPA, IL-8 and MCP-1 induced and secreted from tumor cells upon doxorubicin stimulation may activate surrounding cells expressing the receptors such as neutrophils and monocytes/macrophages in a paracrine fashion. TNF-alpha is a major proinflammatory cytokine, and IL-8 and MCP-1 are major chemoattractants for neutrophils and monocytes/macrophages, respectively. Furthermore, uPA activates matrix metalloproteinase 9 which can truncate and activate IL-8. Thus, the simultaneous induction of TNF-alpha, uPA, IL-8 and MCP-1 may enhance the interaction between tumor and inflammatory/immune cells, and augment cytotoxicity.</abstract><cop>Heidelberg</cop><pub>Springer Nature B.V</pub><doi>10.1007/s00280-003-0665-1</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0344-5704 |
ispartof | Cancer chemotherapy and pharmacology, 2003-11, Vol.52 (5), p.391-398 |
issn | 0344-5704 1432-0843 |
language | eng |
recordid | cdi_proquest_journals_213496314 |
source | SpringerLink Journals - AutoHoldings |
title | Induction of TNF-?, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T23%3A45%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Induction%20of%20TNF-?,%20uPA,%20IL-8%20and%20MCP-1%20by%20doxorubicin%20in%20human%20lung%20carcinoma%20cells&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Niiya,%20Masami&rft.date=2003-11-01&rft.volume=52&rft.issue=5&rft.spage=391&rft.epage=398&rft.pages=391-398&rft.issn=0344-5704&rft.eissn=1432-0843&rft_id=info:doi/10.1007/s00280-003-0665-1&rft_dat=%3Cproquest_cross%3E689862201%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213496314&rft_id=info:pmid/&rfr_iscdi=true |